Send to

Choose Destination
Oncoimmunology. 2012 Aug 1;1(5):768-769.

Targeting the tumor mutanome for personalized vaccination therapy.

Author information

TRON-Translational Oncology at the University Medical Center Mainz; Mainz, Germany.


Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center